tristearin has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calcagno, M; Castelli, F; Contado, C; Cortesi, R; Di Stefano, A; Drechsler, M; Esposito, E; Giuffrida, MC; Longo, F; Morari, M; Ravani, L; Sarpietro, MG; Sozio, P | 1 |
| Cacciari, B; Dalpiaz, A; Mezzena, M; Scalia, S; Strada, M | 1 |
2 other study(ies) available for tristearin and Parkinson Disease
| Article | Year |
|---|---|
Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Calorimetry, Differential Scanning; Cryoelectron Microscopy; Disease Models, Animal; Drug Carriers; Lecithins; Levodopa; Lipids; Mice, Inbred C57BL; Parkinson Disease; Prodrugs; Spectroscopy, Fourier Transform Infrared; Triglycerides | 2015 |
Solid lipid microparticles for the stability enhancement of a dopamine prodrug.
Topics: Delayed-Action Preparations; Dopamine; Dopamine Agents; Drug Compounding; Drug Stability; Humans; Hydrolysis; Parkinson Disease; Particle Size; Plasma; Prodrugs; Triglycerides | 2010 |